331 related articles for article (PubMed ID: 21322014)
1. Glia: initiators and progressors of pathology in Parkinson's disease.
Halliday GM; Stevens CH
Mov Disord; 2011 Jan; 26(1):6-17. PubMed ID: 21322014
[TBL] [Abstract][Full Text] [Related]
2. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease.
Halliday GM; Ophof A; Broe M; Jensen PH; Kettle E; Fedorow H; Cartwright MI; Griffiths FM; Shepherd CE; Double KL
Brain; 2005 Nov; 128(Pt 11):2654-64. PubMed ID: 16000336
[TBL] [Abstract][Full Text] [Related]
3. Interaction between α-synuclein and tau in Parkinson's disease comment on Wills et al.: elevated tauopathy and α-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010; 225: 210-218.
Jellinger KA
Exp Neurol; 2011 Jan; 227(1):13-8. PubMed ID: 20965169
[TBL] [Abstract][Full Text] [Related]
4. Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease.
Banati RB; Daniel SE; Blunt SB
Mov Disord; 1998 Mar; 13(2):221-7. PubMed ID: 9539333
[TBL] [Abstract][Full Text] [Related]
5. Enteric glial cells: new players in Parkinson's disease?
Clairembault T; Leclair-Visonneau L; Neunlist M; Derkinderen P
Mov Disord; 2015 Apr; 30(4):494-8. PubMed ID: 25100667
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of alpha-synuclein in rat substantia nigra results in loss of dopaminergic neurons, phosphorylation of alpha-synuclein and activation of caspase-9: resemblance to pathogenetic changes in Parkinson's disease.
Yamada M; Iwatsubo T; Mizuno Y; Mochizuki H
J Neurochem; 2004 Oct; 91(2):451-61. PubMed ID: 15447678
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study.
Jellinger KA
Acta Neuropathol; 2003 Sep; 106(3):191-201. PubMed ID: 12845452
[TBL] [Abstract][Full Text] [Related]
8. Central role of alpha-synuclein oligomers in neurodegeneration in Parkinson disease.
Kazantsev AG; Kolchinsky AM
Arch Neurol; 2008 Dec; 65(12):1577-81. PubMed ID: 19064744
[TBL] [Abstract][Full Text] [Related]
9. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration.
Morale MC; Serra PA; L'episcopo F; Tirolo C; Caniglia S; Testa N; Gennuso F; Giaquinta G; Rocchitta G; Desole MS; Miele E; Marchetti B
Neuroscience; 2006; 138(3):869-78. PubMed ID: 16337092
[TBL] [Abstract][Full Text] [Related]
10. Glial cells as players in parkinsonism: the "good," the "bad," and the "mysterious" glia.
Mena MA; García de Yébenes J
Neuroscientist; 2008 Dec; 14(6):544-60. PubMed ID: 19029058
[TBL] [Abstract][Full Text] [Related]
11. Glial reactions in Parkinson's disease.
McGeer PL; McGeer EG
Mov Disord; 2008 Mar; 23(4):474-83. PubMed ID: 18044695
[TBL] [Abstract][Full Text] [Related]
12. Neuropathological distinction between Parkinson's dementia and Parkinson's plus Alzheimer's disease.
de la Monte SM; Wells SE; Hedley-Whyte T; Growdon JH
Ann Neurol; 1989 Sep; 26(3):309-20. PubMed ID: 2802531
[TBL] [Abstract][Full Text] [Related]
13. A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease.
Halliday GM; Macdonald V; Henderson JM
Brain; 2005 Oct; 128(Pt 10):2272-80. PubMed ID: 16014651
[TBL] [Abstract][Full Text] [Related]
14. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway.
Marchetti B; Serra PA; L'Episcopo F; Tirolo C; Caniglia S; Testa N; Cioni S; Gennuso F; Rocchitta G; Desole MS; Mazzarino MC; Miele E; Morale MC
Ann N Y Acad Sci; 2005 Dec; 1057():296-318. PubMed ID: 16399902
[TBL] [Abstract][Full Text] [Related]
15. Controversy: is Parkinson's disease a single disease entity? Yes.
Takahashi H; Wakabayashi K
Parkinsonism Relat Disord; 2005 Jun; 11 Suppl 1():S31-7. PubMed ID: 15885626
[TBL] [Abstract][Full Text] [Related]
16. Glial cells and abnormal protein handling in the pathogenesis of Parkinson's disease.
McNaught KS; Lee M; Hyun DH; Jenner P
Adv Neurol; 2001; 86():73-82. PubMed ID: 11554011
[No Abstract] [Full Text] [Related]
17. Alpha-synuclein immunoreactivity in minor salivary gland biopsies of Parkinson's disease patients.
Cersósimo MG; Perandones C; Micheli FE; Raina GB; Beron AM; Nasswetter G; Radrizzani M; Benarroch EE
Mov Disord; 2011 Jan; 26(1):188-90. PubMed ID: 20836135
[No Abstract] [Full Text] [Related]
18. alpha-Synuclein pathology in the neostriatum in Parkinson's disease.
Mori F; Tanji K; Zhang H; Kakita A; Takahashi H; Wakabayashi K
Acta Neuropathol; 2008 Apr; 115(4):453-9. PubMed ID: 18000672
[TBL] [Abstract][Full Text] [Related]
19. Glia: a curtain raiser.
Wilkin GP; Knott C
Adv Neurol; 1999; 80():3-7. PubMed ID: 10410696
[No Abstract] [Full Text] [Related]
20. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
